Recursion Pharmaceuticals, Inc. (RXRX)
Overview
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Explore More Data
Key Information
Stock Snapshot (Updated: Nov 05 04:00 PM EST)
Capital Structure (Updated: Nov 05 04:00 PM EST)
Calendar Events (Upcoming Earnings & Revenue Forecasts)
| Earnings | |
| Earnings Date | 2025-11-05 |
| Earnings Call | 2025-11-05 |
| Avg EPS Estimate | -0.3383 |
| Low EPS Estimate | -0.42 |
| High EPS Estimate | -0.15 |
| Revenue | |
| Avg Revenue Forecast | 21,700,000 |
| Low Revenue Forecast | 16,000,000 |
| High Revenue Forecast | 37,700,000 |
RXRX Liquidity Indicators Shows key metrics that reflect cash availability and short-term payment ability
| Field | Value | Description |
|---|---|---|
| Cash Holdings | $525,110,016 | Cash on hand, which directly shows a company's ability to meet short-term obligations. |
| Quick Ratio | 3.333 | The quick ratio, which excludes inventory, measures short-term solvency; a value above 1 is considered relatively safe. |
| Current Ratio | 3.58 | The current ratio, calculated as current assets divided by current liabilities; the higher the value, the better the liquidity. |
| Total Debt | $88,075,000 | Total liabilities, used together with cash and liquidity ratios to assess debt burden. |
RXRX Profitability Indicators Shows key metrics that reflect overall earnings, margins, and core business profitability
| Field | Value | Description |
|---|---|---|
| EBITDA | $-586,387,008 | EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), which measures the profitability of core operations. |
| Operating Cash Flow | $-383,030,016 | Operating cash flow, which reflects a company's cash-generating ability. |
| Free Cash Flow | $-186,021,744 | Free cash flow, after deducting capital expenditures, which can be used for dividends or reinvestment. |
| Gross Margin | 0.00% | Gross margin; a higher value indicates stronger product profitability. |
| Operating Margin | -916.75% | Operating margin; slightly negative, indicating high operating costs. |
| Profit Margin | 0.00% | Net profit margin, which reflects overall profitability. |
RXRX Leverage & Financial Health Indicators Shows key metrics that reflect debt levels, liquidity, and overall financial stability
| Field | Value | Description |
|---|---|---|
| Debt/Equity Ratio | 9.58% | Low leverage level, indicating the company has low debt pressure. |
| Total Debt | $88,075,000 | Used together with cash and EBITDA to assess debt-paying ability. |
RXRX Growth Indicators Shows key financial metrics that reflect profitability, cash flow, and business expansion
| Field | Value | Description |
|---|---|---|
| Revenue Growth (YoY) | 33.30% | Rapid revenue growth, indicating fast business expansion. |
| Earnings Growth (YoY) | 0.00% | Significant EPS growth, indicating rapid improvement in profitability. |
Financial Data for RXRX (Key ratios, margins, and cash flow)
| Field | Value | Description |
|---|---|---|
| Current Price | $4.96 | Latest stock trading price |
| Price Target (High) | $10 | Analyst highest expected price |
| Price Target (Low) | $3 | Analyst lowest expected price |
| Price Target (Average) | $6.3 | Average target price across analysts |
| Price Target (Median) | $6 | Median of target prices |
| Average Rating Score | 2.63 | Average analyst rating (1=Strong Buy, 5=Sell) |
| Consensus Recommendation | hold | Consensus rating |
| Analyst Coverage Count | 6 | Number of analysts providing estimates |
| Cash Holdings | $525,110,016 | Total cash held by the company |
| Cash per Share | $1.21 | Cash value per outstanding share |
| Total Debt | $88,075,000 | Company's total debt |
| Quick Ratio | 3.333 | Ability to cover short-term liabilities (excludes inventory) |
| Current Ratio | 3.58 | Overall short-term liquidity |
| Debt/Equity Ratio | 9.58% | Leverage ratio: Debt / Equity |
| EBITDA | $-586,387,008 | Earnings before interest, taxes, depreciation & amortization |
| Total Revenue | $64,596,000 | Total company revenue |
| Revenue per Share | $0.18 | Total revenue divided by shares outstanding |
| Gross Profit | 0.00% | Revenue minus cost of goods sold |
| Return on Assets | -39.08% | Net income / Total assets |
| Return on Equity | -86.34% | Net income / Shareholder equity |
| Earnings Growth (YoY) | 0.00% | Year-over-year EPS growth |
| Revenue Growth (YoY) | 33.30% | Year-over-year revenue growth |
| Gross Margin | 0.00% | Gross profit / Total revenue |
| EBITDA Margin | 0.00% | EBITDA / Revenue |
| Operating Margin | -916.75% | Operating income / Revenue |
| Profit Margin | 0.00% | Net income / Revenue |
| Free Cash Flow | $-186,021,744 | Cash left after capital expenditures |
| Operating Cash Flow | $-383,030,016 | Cash from core business operations |
| Currency | USD | Reported in US dollars |
| Last Updated | 2025-11-05 | Data source from Yahoo |